Search

Displaying results 3931 - 3940 of 7502 in total
  1. Drug

    Fendiline

    go.drugbank.com/drugs/DB08980
    ApprovedWithdrawn

    Fendiline is non-selective.

    Categories: Non-Selective Calcium Channel Blockers
  2. Drug

    Citraconic acid

    go.drugbank.com/drugs/DB04734
    Experimental

    Citraconic acid is one of the isomeric dicarboxylic acids produced by the distillation of citric acid, or as metabolites by microorganisms, cis-CH3-C(CO2H)=CHCO2H; the trans-isomer is mesaconic acid.

  3. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume

  4. Drug

    Tesmilifene

    go.drugbank.com/drugs/DB04905
    Investigational

    Tesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast

    Synonyms: N,N-diethyl-2-((4-phenylmethyl)phenoxy)ethanamine
  5. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    At the same time, the agent generally does not see equine use as particular adverse reactions may happen. More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.

  6. Drug

    Recombinant Human Thrombopoietin

    go.drugbank.com/drugs/DB16364
    Investigational

    Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets.

  7. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD). … It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease).

  8. Drug

    PlasmaCord

    go.drugbank.com/drugs/DB16363
    Experimental

    PlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. … [L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).

  9. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  10. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.